Selective Modulator of Cannabinoid Receptor Type 2 Reduces Memory Impairment and Infarct Size During Cerebral Hypoperfusion and Vascular Dementia

Publisher： Bentham Science Publishers

E-ISSN： 1875-5739|13|4|289-302

ISSN： 1567-2026

Source： Current Neurovascular Research, Vol.13, Iss.4, 2016-09, pp. : 289-302

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Cyclooxygenase-2 Inhibitor Reduces Vascular Wall Thickness and Ameliorates Cognitive Impairment in a Cerebral Small Vessel Diseases Rat Model

By  

Current Alzheimer Research, Vol. 12, Iss. 7, 2015-01 ,pp. : 704-710

Bentham Science Publishers

Access to resources Recommend Favorite

Cannabinoid Receptor Type 2 Activation Yields Delayed Tolerance to Focal Cerebral Ischemia

By  

Current Neurovascular Research, Vol. 8, Iss. 2, 2011-05 ,pp. : 145-152

Bentham Science Publishers

Access to resources Recommend Favorite

Neuroprotective Effects of Agomelatine and Vinpocetine Against Chronic Cerebral Hypoperfusion Induced Vascular Dementia

By  

Current Neurovascular Research, Vol. 12, Iss. 3, 2015-01 ,pp. : 240-252

Bentham Science Publishers

Access to resources Recommend Favorite

Selective adenosine A 2a receptor antagonism reduces JNK activation in oligodendrocytes after cerebral ischaemia

By Melani Alessia  

Brain, Vol. 132, Iss. 6, 2009-06 ,pp. : 1480-1495

Oxford University Press

Access to resources Recommend Favorite

The 5-lipoxygenase (5-LOX) Inhibitor Zileuton Reduces Inflammation and Infarct Size with Improvement in Neurological Outcome Following Cerebral Ischemia

By  

Current Neurovascular Research, Vol. 12, Iss. 4, 2015-09 ,pp. : 398-403

Bentham Science Publishers

Access to resources Recommend Favorite